Confo Therapeutics
Belgium - GhentDiagnostics
Focus: Confo Therapeutics is an early-stage biotech company focused on GPCR-targeted therapeutics for metabolic diseases, currently in Series B stage with a single Phase 1 program. Based in Ghent, Belgium, the company operates at pre-revenue stage with minimal pipeline maturity.
Profile data last refreshed 9h ago · AI intelligence enriched 2w ago
Funding Stage
SERIES B
Open Jobs
2
Should You Work at Confo Therapeutics?
AI assessmentConfo is a high-risk, high-learning opportunity best suited for scientists and operators comfortable with preclinical/early-clinical ambiguity in exchange for significant upside if GPCR modulation strategy validates.
Why Work Here
- Join a focused GPCR-biology team at ground floor of company targeting large metabolic disease market with emerging science
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
CFTX-1554
HealthyClinical Trials (1)
NCT05260658Safety and Tolerability of CFTX-1554 in Healthy Subjects
Phase 1Help build intelligence for Confo Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.